Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.71 |
| ▸ | PARP1 | P09874 | 1/20 | 0.71 |
| ▸ | IGF1R | P08069 | 4/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 4/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | NAT1 | P18440 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12406324 | 1.00 | HPGD (0.71) | HPGDPARP1IGF1RTTRINSR | |
| SCHEMBL2173328 | 1.00 | HPGD (0.71) | HPGDPARP1IGF1RTTRINSR | |
| SCHEMBL1299778 | 0.83 | HPGD (1.00) | HPGDPARP1PIM1PIM2PTGS2 | |
| SCHEMBL6865386 | 0.83 | HPGD (1.00) | HPGDPARP1PIM1PIM2PTGS2 | |
| SCHEMBL1299780 | 0.83 | HPGD (1.00) | HPGDPARP1PIM1PIM2PTGS2 | |
| SCHEMBL2174757 | 0.80 | PARP1 (0.79) | HPGDPARP1IGF1RPIM1PIM2 | |
| SCHEMBL2174761 | 0.80 | PARP1 (0.79) | HPGDPARP1IGF1RPIM1PIM2 | |
| SCHEMBL12406319 | 0.80 | PARP1 (0.79) | HPGDPARP1IGF1RPIM1PIM2 | |
| SCHEMBL12406331 | 0.79 | HPGD (0.70) | HPGDPARP1IGF1RPIM1PIM2 | |
| SCHEMBL2172853 | 0.79 | HPGD (0.70) | HPGDPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | claimed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | claimed |
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | AR, ESRRB, KLK3 | HPGD 183/4885PARP1 1402/4885IGF1R 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.